Antibody inhibitors of GDF-8 and uses thereof

Details Antibody inhibitors of GDF-8 and uses thereof Antibody inhibitors of GDF-8 and uses thereof

2008-01-22

2008-01-22

Nickol, Gary (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S135100, C424S141100, C435S326000, C530S387100, C530S388100

Reexamination Certificate

active

07320789

ABSTRACT:
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.

REFERENCES:
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5928893 (1999-07-01), Kang et al.
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2003/0104406 (2003-06-01), Wolfman et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO94-21681 (1994-09-01), None
patent: WO94-26892 (1994-11-01), None
patent: WO96-01845 (1996-01-01), None
patent: WO98/33887 (1998-08-01), None
patent: WO99-24058 (1999-05-01), None
patent: WO99-45949 (1999-09-01), None
patent: WO99-56768 (1999-11-01), None
patent: WO 00-11163 (2000-03-01), None
patent: WO 00-43781 (2000-07-01), None
patent: WO 01/64888 (2001-09-01), None
patent: WO 02-09641 (2002-02-01), None
patent: WO 02-068650 (2002-09-01), None
patent: WO 03/072714 (2003-09-01), None
patent: WO 03/072715 (2003-09-01), None
patent: WO 04-058988 (2004-07-01), None
Suzuki et al., Oncogene 19: 5842-5850, 2000.
Chamov and Ashkanazi, TIBTECH 14: 52-60, 1996.
Wells, Biochemistry 29:8509-8517, 1990.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Rudikoff et al., Proc. Natl. Acad. Sci. 79: 1979-1983, 1982.
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss In Ovariectomized Mice,”J. Bone Miner. Res. 16:1665-1673 (2001).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem. 214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol. 178:343-362 (1996).
Andersson et al., “Repeated In Vivo Determinations of Bone Mineral Density During Parathyroid Hormone Treatment in Ovariectomized Mice,”J. Endocrinol. 170:529-537 (2001).
Ashmore et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and “Double-Muscled” Cattle,”Growth38:501-506 (1974).
Attisano et al., “Activation of Signalling by the Activin Receptor Complex,”Mol. Cell. Biol. 16:1066-1073 (1996).
Bakker et al., Duchenne and Becker Muscular Dystrophies. InDiagnostic Criteria for Neuromuscular Disorders, 2nd ed., Emery, ed., Royal Society of Medicine Press, 1998; pp. 1-4.
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Bogdanovich et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade,”Nature 420:418-421 (2002).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3,”Growth Factors3:35-43 (1990).
Bulfield et al., “X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse,”Proc. Natl. Acad. Sci. U.S.A. 81:1189-1192 (1984).
D'Angelo et al., “Authentic Matrix Vesicles Contain Active Metalloproteases (MMP),”J. Biol. Chem. 276:11347-11353 (2001).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells,”Nature316:701-705 (1985).
Donoghue et al., “Rostrocaudal Gradient of Transgene Expression in Adult Skeletal Muscle,”Proc. Natl. Acad. Sci. U.S.A. 88:5847-5851 (1991).
Emery, “The Muscular Dystrophies,”Lancet359:687-695 (2002).
Escolar et al., “Pharmacologic and Genetic Therapy for Childhood Muscular Dystrophies,”Current Neurology and Neuroscience Reports1:168-174 (2001).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos,”Dev. Biol.208:222-232 (1999).
Gamer et al., “Gdf11 is a Negative Regulator of Chodrogenesis and Myogenesis in the Developing Chick Limb,”Dev. Biol.229:407-420 (2001).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor,”Biochemistry29:6851-6857 (1990).
Gillis, “Multivariate Evaluation of the Functional Recovery Obtained by the Overexpression of Utrophin in Skeletal Muscles of themdxMouse,”Neuromuscular Disorders12:S90-S94 (2002).
Gonzalez-Cadavid et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men With Muscle Wasting,”Proc. Natl. Acad. Sci. U.S.A.95:14938-14943 (1998).
Grady et al., “Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy,”Cell90:729-738 (1997).
Granchelli et al., “Pre-Clinical Screening of Drugs Using themdxMouse,”Neuromuscular Disorders10:235-239 (2000).
Hamrick et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice,”Calcif. Tissue International.71(1):63-68 (2002).
Hamrick et al., “Fermoral Morphology and Cross-Sectional Geometry of Adult Myostatin-Deficient Mice,”Bone27:343-349 (2000).
Hayette et al., “FLRG (Follistatin-Related Gene), A New Target of Chromosomal Rearrangement in Malignant Blood Disorders,”Oncogene16:2949-2954 (1998).
Hill et al., “Regulation of Mystatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains,”Mol. Endocrinol.17:1144-1154 (2003).
Hill et al., “The Myostatin Propeptide and the Follistatin-Related Gene Are Inhibitory Binding Proteins of Myostatin Normal Serum,”J. Biol. Chem.277:40735-40741 (2002).
Hoffman et al., “Conservation of the Duchenne Muscluar Dystrophy Gene in Mice and Humans,”Science238:347-350 (1987).
Hoodless et al., “Mechanisms and Function of Signaling by the TGFβ Superfamily,”Curr. Top. Microbiol. Immunol.228:236-272 (1998).
Huet et al., “Skeletal Muscle Cell Hypertrophy Induced by Inhibitors of Metalloproteases; Myostatin as a Potential Mediator,”Am. J. Physiol. Cell. Physiol.281:C1624-C1634 (2001).
Jiang et al., “Characterization and Identification of the Inhibitory Domain of GDF-8 Propeptide,”Biochem. Biophys. Res. Commun.315:525-531 (2004).
Kambadur et al., “Mutations inmyostatin(GDF8) In Double-Muscled Belgian Blue and Piedmontese Cattle,”Genome Res.7:910-915 (1997).
Kato, “A Secreted Tumor-Suppressor, mac25, with Activin-Binding Activity,”Mol. Med.6:126-135 (2000).
Kessler et al., “Bone Morphogenetic Protein-1: The Type 1 Procollagen C-Proteinase,”Science271:360-362 (1996).
Khurana et al., “Pharmacological Strategies for Musclua

Affiliated with

Also associated with

Rating

Antibody inhibitors of GDF-8 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody inhibitors of GDF-8 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody inhibitors of GDF-8 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2787645